• Akira Hirasawa, Kenta Masuda, Tomoko Akahane, Tomohiko Tsuruta, Kouji Banno, Kazuya Makita, Nobuyuki Susumu, Hiromitsu Jinno, Yuko Kitagawa, Kokichi Sugano, Kenjiro Kosaki, and Daisuke Aoki.
• Department of Obstetrics and Gynecology, School of Medicine, Keio University, 35 Shinanomachi, Shinjyuku-ku, Tokyo 160-8582, Japan. hir-aki@z8.keio.jp
• Jpn. J. Clin. Oncol. 2013 May 1; 43 (5): 515-9.

BackgroundRisk-reducing salpingo-oophorectomy is currently regarded as the most certain primary method for preventing ovarian cancer among BRCA1/2 mutation carriers with hereditary breast and ovarian cancer syndrome. However, risk-reducing salpingo-oophorectomy has rarely been performed in Japan.MethodsWe developed the first system in Japan for performing risk-reducing salpingo-oophorectomy for BRCA1/2 mutation carriers at our university hospital in 2008.ResultsThe indication for risk-reducing salpingo-oophorectomy for patients with hereditary breast/ovarian cancer syndrome is currently limited in Japan. This situation may be because of the limited number of genetic counseling units, the limited number of facilities that can perform BRCA1/2 genetic testing and the fact that prophylactic surgery is not covered by health insurance in Japan.ConclusionsRecent treatment guidelines for breast cancer in Japan recommended risk-reducing salpingo-oophorectomy for BRCA1/2 mutation carriers. Risk-reducing salpingo-oophorectomy should be performed in the framework of the standard therapeutic modality for BRCA1/2 mutation carriers in the near future.

29 keywords...

hide…